Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Regadenoson
Drug ID BADD_D01921
Description Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.
Indications and Usage Diagnostic agent for radionuclide myocardial perfusion imaging (MPI)
Marketing Status approved; investigational
ATC Code C01EB21
DrugBank ID DB06213
KEGG ID D05711
MeSH ID C430916
PubChem ID 219024
TTD Drug ID D0XE1C
NDC Product Code 55150-443; 0409-1401; 76329-3321; 42973-229; 76055-0024; 60505-6116; 72611-874; 59285-029; 69766-103; 68083-175; 16729-477; 71288-201; 0641-6253; 65129-1331; 43598-616; 0469-6501; 62147-0220; 36000-364
UNII 2XLN4Y044H
Synonyms regadenoson | Lexiscan | CVT 3146 | CVT3146 | CVT-3146
Chemical Information
Molecular Formula C15H18N8O5
CAS Registry Number 313348-27-5
SMILES CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)C4C(C(C(O4)CO)O)O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Facial paralysis17.04.03.0080.000127%Not Available
Feeling abnormal08.01.09.0140.001632%Not Available
Feeling cold08.01.09.0080.000516%Not Available
Feeling hot08.01.09.0090.000761%Not Available
Feeling jittery08.01.09.0160.000186%Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.0250.001590%
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Haemorrhage intracranial24.07.04.003; 17.08.01.008--
Headache17.14.01.0010.010225%
Hemiparesis17.01.04.0010.000085%
Hemiplegia17.01.04.0020.000127%Not Available
Hyperhidrosis23.02.03.004; 08.01.03.0280.001878%
Hypersensitivity10.01.03.0030.000541%
Hypertension24.08.02.0010.000668%
Hyperventilation19.01.02.004; 22.02.01.0060.000228%Not Available
Hypoaesthesia23.03.03.081; 17.02.06.0230.001159%Not Available
Hypotension24.06.03.0020.005844%
Immune system disorder10.02.01.001--Not Available
Incontinence20.02.02.004; 17.05.01.006; 07.01.06.0110.000313%Not Available
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.0010.001480%Not Available
Injection site extravasation12.07.03.002; 08.02.03.0020.038684%Not Available
Injection site oedema12.07.03.024; 08.02.03.0240.000186%Not Available
Injection site pain12.07.03.011; 08.02.03.0100.007705%Not Available
Injection site reaction12.07.03.015; 08.02.03.0140.000330%
Insomnia19.02.01.002; 17.15.03.002--
Lethargy17.02.04.003; 08.01.01.008; 19.04.04.0040.000372%
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.0050.000186%Not Available
Loss of consciousness17.02.04.0040.001387%Not Available
Malaise08.01.01.0030.003155%
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 7 Pages